Itope,” which could be capable to IL-18RAP Proteins Recombinant Proteins induce particular CTLs, but 4 epitopes have been determined as a “dead epitope”. Compared using the IFN- ELISPOT assay, the results of murine-immunoproteasome digestion assay have been substantially matched the results of CTL induction (11 of 12 epitopes: 91.7 ). Conclusions Murine-immunoproteasome digestion assay could predict the CTL induction having a higher degree of accuracy. We concluded that murine-immunoproteasome digestion assay tactic might be a prognostic method for IFN- ELISPOT assay making use of an HLA-expressing mice model. In addition, our final results suggested that the positions of each epitope peptide are critical for the design of SLP vaccines. Murineimmunoproteasome digestion assay is extremely helpful to develop “suitable” multi-valent SLP vaccines.Journal for ImmunoTherapy of Cancer 2016, four(Suppl 1):Page 194 ofTumor MicroenvironmentP364 Comparative evaluation of frequency, phenotypic profile and transcriptome of dendritic cell (DC) subsets in tonsillar cancer (TC) and benign tonsils Milad Abolhalaj1, David Askmyr2, Kristina Lundberg1, Ann-Sofie Albrekt1, Lennart Greiff2, Malin Lindstedt1 1 Department of Immunotechnology, Lund University, Lund, Skane Lan, Sweden; 2ENT Division, Lund University Hospital, Lund, Skane Lan, Sweden Correspondence: Milad Abolhalaj ([email protected]) Journal for ImmunoTherapy of Cancer 2016, four(Suppl 1):P364 Background Head and neck cancer (HNC), including TC, would be the 6th most common group of cancers worldwide. Survival prices with traditional treatments are unsatisfactory and treatment-associated unwanted side effects marked, necessitating improvement of novel therapeutic approaches. Arguably, DC-mediated immunotherapy is one such solution, owing to the outstanding possible of DCs to elicit tumor-specific immune responses. Our function presents frequency at the same time as transcriptional and phenotypical assessments of myeloid and plasmacytoid DC subsets in TC and benign tonsils to fulfill a descriptive need of DC characterization in DC-mediated immunotherapy context. Approaches From biopsies of TC tissue (n = 4) and benign tonsils (n = 4), DC subsets were identified and sorted through an 8-color flow cytometry Ab panel. Sorted cells have been run on a human transcriptome array and gene expression profiles of your subsets in TC have been when compared with their peers with benign tonsils. Two fold upregulated subset-specific gene signatures have been determined by the intersection derived from separate twogroup comparison tests against other subsets. They had been then analyzed and candidate genes had been extracted depending on association with crosspresentation, endocytosis, and signaling activities. A set of selected candidate markers was investigated in the protein level via flow cytometry (about 15 benign and ten TC samples). Benefits DCs have been much more frequent amongst CD45+ leukocytes in TC in comparison to benign tonsils and showed an elevated myeloid CD11c+/plasmacytoid CD123+ ratio. In agreement, some statistically significant adjustments have been LI-Cadherin/Cadherin-17 Proteins supplier observed in various subsets exactly where CD123+ DCs have been less frequent in TC compared to benign tonsils when CD1c- CD141- DCs have been a lot more frequent. In contrast, no substantial variations were detected in DC subsets’ gene expression profiles in between TC and benign tonsils. Lists of subset-specific candidate genes have been generated and some of them have been confirmed at protein level, e.g., CD206 and CD207 on the CD1c+ DCs in TC and benign tonsils. Conclusions DCs are present in TC and benign tonsil tissue.